ArticleBMC gastroenterology2026
Gastrointestinal bleeding risk in cirrhotic portal vein thrombosis: focus on thrombus extension to superior mesenteric vein.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND &
aimsPortal vein thrombosis (PVT) is a prevalent cirrhosis complication linked to gastrointestinal bleeding. This study aims to assess correlations between PVT classification and the risk of bleeding in patients with cirrhotic PVT.
methodsThis retrospective study included 380 hospitalized cirrhotic patients complicated by PVT, categorized into bleeding and non-bleeding groups based on history of gastrointestinal bleeding. Patients were followed for 12 months to calculate bleeding and recurrence rates. PVT was classified as non-extending or extending, based on the anatomical location and extent. Multivariate logistic regression analyses and propensity score matching (PSM) were used to evaluate the impact of superior mesenteric vein thrombosis (SMVT) extension on bleeding outcomes.
resultsOf 380 patients, 223 (58.7%) were in the bleeding group and 157 (41.3%) in the non-bleeding group; 267 (70.3%) had non-extending PVT and 113 (29.7%) extending PVT (89 involving SMV). During follow-up, 201 (55.5%) experienced bleeding, with a 63.7% recurrence rate in the initial bleeding group. Extended PVT and SMVT-positive patients were significantly more likely to have higher baseline bleeding rates, 12-month bleeding rates, and recurrence rates compared with non-extended and SMVT-negative patients (all P < 0.05). Multivariate analysis identified SMVT extension as an independent risk factor associated with baseline (OR = 2.194; P = 0.010) and 12-month bleeding (OR = 1.962; P = 0.018). PSM confirmed significant associations between SMVT extension and gastrointestinal bleeding at baseline (P = 0.035) and 12 months (P = 0.033).
conclusionsIn patients with cirrhosis and PVT, the extension into the SMV is significantly associated with an increased risk of gastrointestinal bleeding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.